Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]

Malfertheiner, P. ; O'Connor, H. J. ; Genta, R. M. ; Unge, P. ; Axon, A. T. R.

Oxford UK : Blackwell Science Ltd.
Published 2002
ISSN:
1365-2036
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
Type of Medium:
Electronic Resource
URL:
_version_ 1798290074998145025
autor Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
autorsonst Unge, P.
Axon, A. T. R.
book_url http://dx.doi.org/10.1046/j.1365-2036.16.s3.1.x
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLZ24220452X
insertion_date 2012-04-27
issn 1365-2036
journal_name Alimentary pharmacology & therapeutics
materialart 1
notes Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
package_name Blackwell Publishing
publikationsjahr_anzeige 2002
publikationsjahr_facette 2002
publikationsjahr_intervall 7999:2000-2004
publikationsjahr_sort 2002
publikationsort Oxford UK
publisher Blackwell Science Ltd.
reference 16 (2002), S. 0
search_space articles
shingle_author_1 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
shingle_author_2 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
shingle_author_3 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
shingle_author_4 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
shingle_catch_all_1 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
Blackwell Science Ltd.
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
1365-2036
13652036
shingle_catch_all_2 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
Blackwell Science Ltd.
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
1365-2036
13652036
shingle_catch_all_3 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
Blackwell Science Ltd.
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
1365-2036
13652036
shingle_catch_all_4 Malfertheiner, P.
O'Connor, H. J.
Genta, R. M.
Unge, P.
Axon, A. T. R.
Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
Blackwell Science Ltd.
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
1365-2036
13652036
shingle_title_1 Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
shingle_title_2 Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
shingle_title_3 Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
shingle_title_4 Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
source_archive Blackwell Publishing Journal Backfiles 1879-2005
timestamp 2024-05-06T08:10:57.517Z
titel Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
titel_suche Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
topic WW-YZ
uid nat_lic_papers_NLZ24220452X